GlobeNewswire

AVITA Medical Reports Third Quarter Results
05/11/2026
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic [...]
The Joint Corp. Reports Third Quarter 2026 Financial Results
05/11/2026
- Revenue Increases to $13.6 Million - - Net Income from Continuing Operations Increases by $1.2 Million to $1.5 Million and Adjusted EBITDA From Continuing Operations Increases by $0.9 Million to $2.3 Million - - [...]
Sight Sciences to Present at Two Upcoming Investor Conferences
05/11/2026
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/11/2026
NEEDHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
05/11/2026
Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion Using TAMP [...]
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
05/11/2026
Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or [...]
Equillium to Participate in Upcoming Investor Conferences
05/11/2026
LA JOLLA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today announced that [...]
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
05/11/2026
Trial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168) Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a favorable safety and [...]
What Published Human Trials Show About a Postbiotic in Women Ages 40 to 55
05/11/2026
Three peer-reviewed studies behind the two ingredients in Calroy Health Sciences’ Selentra HP™ measured inflammatory markers, skin health, and bone mineral density in women during and after the menopause transition. [...]
Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
05/11/2026
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]
Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
05/11/2026
FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE [...]
Osteal Therapeutics Announces Three Scientific Presentations Related to the APEX Clinical Trial Program at the 2026 AAHKS Annual Meeting
05/11/2026
Presentations will address 24-month treatment outcomes, systemic antibiotic exposure, and new treatment strategies for recalcitrant periprosthetic joint infection DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Osteal [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum